Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Paper
  • Published:

The HTLV-I Tax oncoprotein targets the retinoblastoma protein for proteasomal degradation

Abstract

Human T-cell leukemia virus type-I (HTLV-I), the etiologic agent of adult T-cell leukemia (ATL), is estimated to affect 10–20 million people worldwide. The transforming ability of HTLV-I has been largely attributed to the viral protein Tax, which modulates the activity of several well-known cell cycle regulators. An important cell cycle regulator, the retinoblastoma (Rb) protein, is often inactivated in many cancers including virally induced cancers. Upon examination of Rb status, we observed a decrease in Rb protein expression in HTLV-1-infected cell lines as well as in ex vivo ATL patient samples. Transient transfection assays indicated that decreased Rb protein levels were Tax dependent. Here, we demonstrate for the first time that Tax directly associates with Rb. This interaction was localized within the B pocket of Rb and the C-terminus of Tax (aa 245–353). Within the C-terminus of Tax, we have identified an LXCXE-like motif, that when mutated resulted in the loss of Tax/Rb interaction. Furthermore, through the use of proteasome inhibitors, such as MG-132, in vivo and proteasome degradation assays in vitro, we found that Tax destabilizes the hypo-phosphorylated (active) form of Rb via the proteasome pathway. Therefore, we propose a model whereby Tax targets Rb to the proteasome by acting as a molecular bridge bringing Rb into contact with the proteasome for degradation.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7
Figure 8

Similar content being viewed by others

References

  • Adams J . (2003). Cancer Treat. Rev., 29 (Suppl 1), 3–9.

  • Akagi T, Ono H and Shimotohno K . (1996). Oncogene, 12, 1645–1652.

  • Almond JB and Cohen GM . (2002). Leukemia, 16, 433–443.

  • Antelman D, Perry S, Hollingsworth R, Gregory RJ, Driscoll B, Fung YK and Bookstein R . (1997). Oncogene, 15, 2855–2866.

  • Bex F, Yin MJ, Burny A and Gaynor RB . (1998). Mol. Cell. Biol., 18, 2392–2405.

  • Blagosklonny MV and Pardee AB . (2002). Cell Cycle, 1, 103–110.

  • Boyer SN, Wazer DE and Band V . (1996). Cancer Res., 56, 4620–4624.

  • Buchkovich K, Duffy LA and Harlow E . (1989). Cell, 58, 1097–1105.

  • Chellappan S, Kraus VB, Kroger B, Munger K, Howley PM, Phelps WC and Nevins JR . (1992). Proc. Natl. Acad. Sci. USA, 89, 4549–4553.

  • Chen WJ and Lin JK . (2004). J. Biol. Chem., 279, 13496–13505.

  • Darnell GA, Antalis TM, Johnstone RW, Stringer BW, Ogbourne SM, Harrich D and Suhrbier A . (2003). Mol. Cell. Biol., 23, 6520–6532.

  • de la Fuente C, Santiago F, Chong SY, Deng L, Mayhood T, Fu P, Stein D, Denny T, Coffman F, Azimi N, Mahieux R and Kashanchi F . (2000). J. Virol., 74, 7270–7283.

  • de la Fuente C, Wang L, Wang D, Deng L, Wu K, Li H, Stein LD, Denny T, Coffman F, Kehn K, Baylor S, Maddukuri A, Pumfery A and Kashanchi F . (2003). Mol. Cell. Biochem., 245, 99–113.

  • Dunaief JL, King A, Esumi N, Eagen M, Dentchev T, Sung CH, Chen S and Zack DJ . (2002). Curr. Eye Res., 24, 392–396.

  • Dyson N, Guida P, Munger K and Harlow E . (1992). J. Virol., 66, 6893–6902.

  • Egan C, Jelsma TN, Howe JA, Bayley ST, Ferguson B and Branton PE . (1988). Mol. Cell. Biol., 8, 3955–3959.

  • Fan S, Yuan R, Ma YX, Xiong J, Meng Q, Erdos M, Zhao JN, Goldberg ID, Pestell RG and Rosen EM . (2001). Oncogene, 20, 4827–4841.

  • Fattaey AR, Harlow E and Helin K . (1993). Mol. Cell. Biol., 13, 7267–7277.

  • Fujii M, Niki T, Mori T, Matsuda T, Matsui M, Nomura N and Seiki M . (1991). Oncogene, 6, 1023–1029.

  • Gatza ML, Watt JC and Marriott SJ . (2003). Oncogene, 22, 5141–5149.

  • Gitlin SD, Lindholm PF, Marriott SJ and Brady JN . (1991). J. Virol., 65, 2612–2621.

  • Gonzalez SL, Stremlau M, He X, Basile JR and Munger K . (2001). J. Virol., 75, 7583–7591.

  • Gottesfeld JM, Johnson DL and Nyborg JK . (1996). Mol. Cell. Biol., 16, 1777–1785.

  • Grassmann R, Berchtold S, Radant I, Alt M, Fleckenstein B, Sodroski JG, Haseltine WA and Ramstedt U . (1992). J. Virol., 66, 4570–4575.

  • Grossman WJ, Kimata JT, Wong FH, Zutter M, Ley TJ and Ratner L . (1995). Proc. Natl. Acad. Sci. USA, 92, 1057–1061.

  • Grossman WJ and Ratner L . (1996). J Acquir. Immune Defic. Syndr. Hum. Retrovirol., 13 (Suppl 1), S162–S169.

  • Haller K, Wu Y, Derow E, Schmitt I, Jeang KT and Grassmann R . (2002). Mol. Cell. Biol., 22, 3327–3338.

  • Hangaishi A, Ogawa S, Imamura N, Miyawaki S, Miura Y, Uike N, Shimazaki C, Emi N, Takeyama K, Hirosawa S, Kamada N, Kobayashi Y, Takemoto Y, Kitani T, Toyama K, Ohtake S, Yazaki Y, Ueda R and Hirai H . (1996). Blood, 87, 4949–4958.

  • Haoudi A, Daniels RC, Wong E, Kupfer G and Semmes OJ . (2003). J. Biol. Chem., 278, 37736–37744.

  • Harbour JW and Dean DC . (2000). Nat. Cell. Biol., 2, E65–E67.

  • Hatta Y, Yamada Y, Tomonaga M and Koeffler HP . (1997). Leukemia, 11, 984–989.

  • He Q, Huang Y and Sheikh MS . (2003). Oncogene, 23, 2554–2558.

  • Helt AM and Galloway DA . (2003). Carcinogenesis, 24, 159–169.

  • Hemelaar J, Bex F, Booth B, Cerundolo V, McMichael A and Daenke S . (2001). J. Virol., 75, 11106–11115.

  • Hollsberg P . (1999). Microbiol. Mol. Biol. Rev., 63, 308–333.

  • Iha H, Kasai T, Kibler KV, Iwanaga Y, Tsurugi K and Jeang KT . (2000). AIDS Res. Hum. Retroviruses, 16, 1633–1638.

  • Ishida S, Shudo K, Takada S and Koike K . (1995). Cell Growth Differ., 6, 229–237.

  • Iwanaga R, Ohtani K, Hayashi T and Nakamura M . (2001). Oncogene, 20, 2055–2067.

  • Jiang H, Lu H, Schiltz RL, Pise-Masison CA, Ogryzko VV, Nakatani Y and Brady JN . (1999). Mol. Cell. Biol., 19, 8136–8145.

  • Johnson DG and Schneider-Broussard R . (1998). Front. Biosci., 3, d447–d448.

  • Jones DL, Thompson DA and Munger K . (1997). Virology, 239, 97–107.

  • Kalejta RF, Bechtel JT and Shenk T . (2003). Mol. Cell. Biol., 23, 1885–1895.

  • Kalejta RF and Shenk T . (2003). Proc. Natl. Acad. Sci. USA, 100, 3263–3268.

  • Kashanchi F, Khleif SN, Duvall JF, Sadaie MR, Radonovich MF, Cho M, Martin MA, Chen SY, Weinmann R and Brady JN . (1996). J. Virol., 70, 5503–5510.

  • Kehn K, Deng L, De La Fuente C, Strouss K, Wu K, Maddukuri A, Baylor S, Rufner R, Pumfery A, Bottazzi ME and Kashanchi F . (2004). Retrovirology, 1, 6.

  • Kitagawa M, Higashi H, Jung HK, Suzuki-Takahashi I, Ikeda M, Tamai K, Kato J, Segawa K, Yoshida E, Nishimura S and Taya Y . (1996). EMBO J., 15, 7060–7069.

  • Knudsen KE, Fribourg AF, Strobeck MW, Blanchard JM and Knudsen ES . (1999). J. Biol. Chem., 274, 27632–27641.

  • Lee JY, Leonhardt LG and Obeid LM . (1998). Biochem. J., 334 (Part 2), 457–461.

  • Lenz HJ . (2003). Cancer Treat. Rev., 29 (Suppl 1), 41–48.

  • Li J, Li H and Tsai MD . (2003). Biochemistry, 42, 6921–6928.

  • Liu B, Liang MH, Kuo YL, Liao W, Boros I, Kleinberger T, Blancato J and Giam CZ . (2003). Mol. Cell. Biol., 23, 5269–5281.

  • Low KG, Dorner LF, Fernando DB, Grossman J, Jeang KT and Comb MJ . (1997). J. Virol., 71, 1956–1962.

  • Matsumoto K, Shibata H, Fujisawa JI, Inoue H, Hakura A, Tsukahara T and Fujii M . (1997). J. Virol., 71, 4445–4451.

  • Matsuoka M . (2003). Oncogene, 22, 5131–5140.

  • Meriin AB, Gabai VL, Yaglom J, Shifrin VI and Sherman MY . (1998). J. Biol. Chem., 273, 6373–6379.

  • Mori N . (1997). Eur. J. Haematol., 58, 114–120.

  • Morris EJ and Dyson NJ . (2001). Adv. Cancer Res., 82, 1–54.

  • Nahle Z, Polakoff J, Davuluri RV, McCurrach ME, Jacobson MD, Narita M, Zhang MQ, Lazebnik Y, Bar-Sagi D and Lowe SW . (2002). Nat. Cell. Biol., 4, 859–864.

  • Nakayama K, Yamada Y, Koji T, Hayashi T, Tomonaga M and Kamihira S . (2000). Leuk. Res., 24, 299–305.

  • Neuveut C, Low KG, Maldarelli F, Schmitt I, Majone F, Grassmann R and Jeang KT . (1998). Mol. Cell. Biol., 18, 3620–3632.

  • Nevins JR . (2001). Hum. Mol. Genet., 10, 699–703.

  • Ohtani K, Iwanaga R, Arai M, Huang Y, Matsumura Y and Nakamura M . (2000). J. Biol. Chem., 275, 11154–11163.

  • Pajonk F and McBride WH . (2001). Radiat. Res., 156, 447–459.

  • Pan W, Cox S, Hoess RH and Grafstrom RH . (2001). Cancer Res., 61, 2885–2891.

  • Patrick DR, Oliff A and Heimbrook DC . (1994). J. Biol. Chem., 269, 6842–6850.

  • Petropoulos L and Hiscott J . (1998). Virology, 252, 189–199.

  • Plath T, Peters M, Detjen K, Welzel M, von Marschall Z, Radke C, Wiedenmann B and Rosewicz S . (2002). J. Natl. Cancer Inst., 94, 129–142.

  • Qin XQ, Chittenden T, Livingston DM and Kaelin Jr WG . (1992). Genes Dev., 6, 953–964.

  • Rock KL, Gramm C, Rothstein L, Clark K, Stein R, Dick L, Hwang D and Goldberg AL . (1994). Cell, 78, 761–771.

  • Rousset R, Desbois C, Bantignies F and Jalinot P . (1996). Nature, 381, 328–331.

  • Ruben S, Poteat H, Tan TH, Kawakami K, Roeder R, Haseltine W and Rosen CA . (1988). Science, 241, 89–92.

  • Ruemmele FM, Beaulieu JF, O'Connell J, Bennett MW, Seidman EG and Lentze MJ . (2002). Biochem. Biophys. Res. Commun., 290, 1308–1314.

  • Sage J, Miller AL, Perez-Mancera PA, Wysocki JM and Jacks T . (2003). Nature, 424, 223–228.

  • Salcedo M, Garrido E, Taja L and Gariglio P . (1995). Arch Med Res, 26 (Spec No.), S157–S162.

  • Sambrook J and Russell DW . (2001). Molecular Cloning: A Laboratory Manual 3rd edn. Cold Spring Harbor Laboratory Press: Cold Spring Harbor, NY.

    Google Scholar 

  • Santiago F, Clark E, Chong S, Molina C, Mozafari F, Mahieux R, Fujii M, Azimi N and Kashanchi F . (1999). J. Virol., 73, 9917–9927.

  • Schmitt I, Rosin O, Rohwer P, Gossen M and Grassmann R . (1998). J. Virol., 72, 633–640.

  • Scott PH, Cairns CA, Sutcliffe JE, Alzuherri HM, McLees A, Winter AG and White RJ . (2001). J. Biol. Chem., 276, 1005–1014.

  • Sellers WR, Novitch BG, Miyake S, Heith A, Otterson GA, Kaye FJ, Lassar AB and Kaelin Jr WG . (1998). Genes Dev., 12, 95–106.

  • Sellers WR, Rodgers JW and Kaelin Jr WG . (1995). Proc. Natl. Acad. Sci. USA, 92, 11544–11548.

  • Semmes OJ and Jeang KT . (1992). Virology, 188, 754–764.

  • Slansky JE, Li Y, Kaelin WG and Farnham PJ . (1993). Mol. Cell. Biol., 13, 1610–1618.

  • Smith MR and Greene WC . (1990). Genes Dev., 4, 1875–1885.

  • Song S, Liem A, Miller JA and Lambert PF . (2000). Virology, 267, 141–150.

  • Suzuki T, Hirai H, Murakami T and Yoshida M . (1995). Oncogene, 10, 1199–1207.

  • Suzuki T, Kitao S, Matsushime H and Yoshida M . (1996). EMBO J., 15, 1607–1614.

  • Suzuki T and Yoshida M . (1997). Leukemia, 11 (Suppl 3), 14–16.

  • Takahashi R, Deveraux Q, Tamm I, Welsh K, Assa-Munt N, Salvesen GS and Reed JC . (1998). J. Biol. Chem., 273, 7787–7790.

  • Tanaka A, Takahashi C, Yamaoka S, Nosaka T, Maki M and Hatanaka M . (1990). Proc. Natl. Acad. Sci. USA, 87, 1071–1075.

  • Uchiyama T . (1997). Annu. Rev. Immunol., 15, 15–37.

  • Vinitsky A, Michaud C, Powers JC and Orlowski M . (1992). Biochemistry, 31, 9421–9428.

  • Wang H, Machesky NJ and Mansky LM . (2004). J. Virol., 78, 1503–1512.

  • Wang J, Sampath A, Raychaudhuri P and Bagchi S . (2001). Oncogene, 20, 4740–4749.

  • Weintraub SJ, Chow KN, Luo RX, Zhang SH, He S and Dean DC . (1995). Nature, 375, 812–815.

  • Welch PJ and Wang JY . (1993). Cell, 75, 779–790.

  • Whyte P, Williamson NM and Harlow E . (1989). Cell, 56, 67–75.

  • Wu K, Bottazzi ME, De La Fuente C, Deng L, Gitlin SD, Maddukuri A, Dadgar S, Li H, Vertes A, Pumfery A and Kashanchi F . (2003). J. Biol. Chem, 279, 495–508.

  • Yamaoka S, Tobe T and Hatanaka M . (1992). Oncogene, 7, 433–437.

  • Yoshida M . (2001). Annu. Rev. Immunol., 19, 475–496.

  • Zarkowska T and Mittnacht S . (1997). J. Biol. Chem., 272, 12738–12746.

  • Zetterberg A, Larsson O and Wiman KG . (1995). Curr. Opin. Cell Biol., 7, 835–842.

Download references

Acknowledgements

We acknowledge the Kashanchi lab members for their constructive criticism and helpful discussions. We thank Dr Scott Gitlin (University of Michigan, Ann Arbor, MI, USA) for the Tax polyclonal antibody, Dr Sibylle Mittnacht (Chester Beatty Laboratories, London, UK) for the GST-Rb constructs, Dr William Sellers (Harvard Medical School, Boston, MA, USA) for the HA-Rb construct, and Dr Warner Greene (Gladstone Institute of Virology and Immunology, CA, USA) for the pBC12-Tax M44 and -M41 constructs. We also thank Dr Chen Zeng (Department of Physics, The George Washington University) for his assistance in molecular modeling of Rb and Tax proteins (data not shown). K Kehn was supported by a predoctoral research fellowship from the DOD Breast Cancer Research Program (DAMD17-03-1-0198). C de la Fuente was supported by NIH Grant;AI061560. R Mahieux received financial support from Association pour la Recherche sur le Cancer. This work was supported in part by NIH Grants AI44357, AI43894, and AI061560 to F Kashanchi and partially by a Research Enhancement Fund (REF) from The George Washington University to F Kashanchi and A Vertes.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Fatah Kashanchi.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kehn, K., Fuente, C., Strouss, K. et al. The HTLV-I Tax oncoprotein targets the retinoblastoma protein for proteasomal degradation. Oncogene 24, 525–540 (2005). https://doi.org/10.1038/sj.onc.1208105

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1208105

Keywords

This article is cited by

Search

Quick links